Health-care workers (HCW) are at high risk for SARS-CoV-2 infection and, if asymptomatic, for transmitting the virus to fragile cancer patients. We monitored all asymptomatic HCWs of a cancer institute (94% of all employees agreed to enter the study) with the rapid serological test, VivaDiag™, identifying SARS-CoV-2 associated-IgM/IgG. The tests were performed at time 0 (n = 606) and after 14 days (n = 393). Overall, the VivaDiag™ results of nine HCWs (1.5%) were positive, with one confirmed to be SARS-CoV-2-positive after oropharyngeal swab testing by RT-PCR. At time 0, all nine cases showed IgM expression while IgG was detected in only one. After 14 days, IgM persisted in all the cases, while IgG became evident in four. A chemiluminescence immunoassay (CLIA) confirmed IgM positivity in 5/13 VivaDiag™ positive cases and IgG positivity in 4/5 VivaDiag™ positive cases. Our study suggests that the VivaDiag™ test can be of help in identifying SARS-CoV-2 infected people in cohorts of subjects with a high prevalence.
CITATION STYLE
Paradiso, A. V., De Summa, S., Silvestris, N., Tommasi, S., Tufaro, A., Larocca, A. M. V., … De Palma, G. (2021). Prospective observational COVID-19 screening and monitoring of asymptomatic cancer center health-care workers with a rapid serological test. Diagnostics, 11(6). https://doi.org/10.3390/diagnostics11060975
Mendeley helps you to discover research relevant for your work.